Company · BBTX
Bambusa Therapeutics, Inc.
Nasdaq's symbol directory lists BBTX on Nasdaq as “Bambusa Therapeutics, Inc. - Common stock”.
In the 12 months to Nov 8, 2026: insiders bought on 3 occasions ($52.6M); 2 filings by holders of 5% or more; 1 company report (Form 8-K, since May 26, 2026).
All insider filings at the SEC · Appeared in No. 44, No. 43
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- RA CAPITAL MANAGEMENT, L.P. bought $46.6M
- Salvia Investment GmbH bought $6.0M
Every trade (3)
- BUYRA CAPITAL MANAGEMENT, L.P. bought $40.0M
- BUYSalvia Investment GmbH bought $6.0M
- BUYRA CAPITAL MANAGEMENT, L.P. bought $6.6M
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- RA Capital Management, L.P. 14.6%
- ATHOS KG 9.2%
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Amendments to articles or bylaws; change in fiscal year; Regulation FD disclosure Nov 3, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.